ReviewJournal of clinical medicine2023
An Update on the Genetics of IgA Nephropathy.
Review in Journal of clinical medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 9 citations in OpenAlex.
- From Susceptibility Loci to Therapeutic Targets: The Genetic Architecture of IgA Nephropathy.International journal of molecular sciences · 2026Review
- Unmasking orthostatic hypotension after cellular therapy: risk factors, implications, and clinical significance.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
- Treatment approaches for large traumatic cyclodialysis clefts in phakic eyes: A systematic review and proposal for standardized reporting.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026Article
- The expanding role of biomarkers in the management of IgA nephropathy.Kidney international supplements · 2026Review
- Management of IgA nephropathy and the expanding role of immunomodulation.Kidney international supplements · 2026Review
- IgA nephropathy: an overview of the disease, its pathophysiology, and involvement of the gut-kidney axis.Kidney international supplements · 2026Review
- FMultifunctional magnetic resonance imaging for the assessment of renal pathological alterations in IgA nephropathy.BMC nephrology · 2026Article
- Comparison of the predictive performance of machine learning and conventional logistic regression models for poor discharge outcomes in patients with Aneurysmal subarachnoid hemorrhage: A retrospective cohort study.Neurosurgical review · 2026Article
- Development and validation of a predictive model for rapid renal function decline in early IgA nephropathy: a multicenter retrospective study.Frontiers in medicine · 2026Article
- Cancer gene therapy: historical perspectives, current applications, and future directions.Functional & integrative genomics · 2025Review
- Pathogenic variants prevalence patients with diabetic kidney disease in Japan: A descriptive study.Journal of diabetes investigation · 2025Article
- LncRNAs and IgA nephropathy: underlying molecular pathways and clinical applications.Clinical and experimental medicine · 2025Review
- Single-Cell RNA-Sequencing Analysis Provides Insights into IgA Nephropathy.Biomolecules · 2025Review
- What is new in the pathogenesis and treatment of IgA glomerulonephritis.World journal of nephrology · 2024Review
- Towards Risk Stratification in Clinical Care for IgA Nephropathy: Genetic Risk Scores: Comments on the Study "Clinical Application of Polygenic Risk Score in IgA Nephropathy".Phenomics (Cham, Switzerland) · 2024Article
- Contemporary review of IgA nephropathy.Frontiers in immunology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Immunoglobulin A (IgA) nephropathy (IgAN), the most common form of glomerulonephritis, is one of the leading causes of end-stage kidney disease (ESKD). It is widely believed that genetic factors play a significant role in the development of IgAN. Previous studies of IgAN have provided important insights to unravel the genetic architecture of IgAN and its potential pathogenic mechanisms. The genome-wide association studies (GWASs) together have identified over 30 risk loci for IgAN, which emphasizes the importance of IgA production and regulation in the pathogenesis of IgAN. Follow-up fine-mapping studies help to elucidate the candidate causal variant and the potential pathogenic molecular pathway and provide new potential therapeutic targets. With the rapid development of next-generation sequencing technologies, linkage studies based on whole-genome sequencing (WGS)/whole-exome sequencing (WES) also identify rare variants associated with IgAN, accounting for some of the missing heritability. The complexity of pathogenesis and phenotypic variability may be better understood by integrating genetics, epigenetics, and environment. We have compiled a review summarizing the latest advancements in genetic studies on IgAN. We similarly summarized relevant studies examining the involvement of epigenetics in the pathogenesis of IgAN. Future directions and challenges in this field are also proposed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.